Trial Profile
A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Substitution, Crossover, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pf 06650833 Delivered in Multiple Formulations in Healthy Subjects Under Fasted and Fed Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Zimlovisertib (Primary) ; Zimlovisertib (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Pfizer
- 08 Nov 2017 Results from the single and multiple ascending dose (SAD, MAD) studies of PF-06650833 in healthy subjects assessing safety and efficacy, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov